Evaluation of the Safety and Efficacy of GLK-321 in Subjects With Demodex Blepharitis
Study sponsor: Glaukos Corporation
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2026-09Estimated
Enrollment · participants250Estimated
Source updated2026-02-27Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.